If you receive a denial letter from your insurer, seek legal advice before appealing the decision, says a leading disability ...

Friedreich’s ataxia (FA) is a neurodegenerative disease most people have never heard of, and it remains widely misunderstood ...

A medication used in dogs suffering from osteoarthritis is facing backlash after thousands of patients have experienced ...

The biotech has signed a non-dilutive funding deal with Oberland Capital as it awaits an FDA ruling on its spinocerebellar ...

Steminent Biotherapeutics specializes in developing innovative stem cell-based therapeutics that offer new hope for patients ...

Biohaven will use the money to bankroll commercial preparations for the spinocerebellar ataxia drug candidate troriluzole, ...

Biogen Netherlands has received marketing authorisation from the UK’s Medicines and Healthcare products Regulatory Agency ...

Currently under review in the U.S. for a rare genetic disorder, the drug is seen by some investors as critical to Biohaven’s ...

Biogen’s Skyclarys (omaveloxolone) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as the ...

We found that mice lacking cystatin B develop myoclonic seizures and ataxia, similar to symptoms seen in the human disease. The principal cytopathology appears to be a loss of cerebellar granule ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Skyclarys (omaveloxolone), the first treatment ...